Pharmafile Logo
Pharmafocus logo
Advanced Search

NHE3

Showing 1 posts of 1 posts found.

Astrazeneca image

AZ licences renal disease compound

October 9, 2012
Research and Development, Sales and Marketing Ardelyx, AstraZeneca, NHE3

AstraZeneca has signed an agreement giving it worldwide exclusive rights to California-based Ardelyx’s NHE3 inhibitor programme targeting liver and kidney …

News
The Gateway to Local Adoption Series

Latest content

Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis

October 7, 2026

Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial

October 6, 2026

ESTEVE CDMO adds $17.5m to Illinois expansion

October 6, 2026

AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials

October 4, 2026

Brenntag and dsm-firmenich expand biopharma vitamin partnership

October 4, 2026